diaziquone has been researched along with Acute Disease in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baer, MR; Block, AW; Bloomfield, CD; Carroll, AJ; Farag, SS; Koduru, PR; Kolitz, JE; Larson, RA; Mayer, RJ; Moore, JO; Mrózek, K; Pettenati, MJ; Powell, BL; Ruppert, AS; Schiffer, CA; Stamberg, J; Stone, RM; Vardiman, JW | 1 |
| Bloomfield, CD; Carroll, AJ; Edwards, CG; Kolitz, JE; Larson, RA; Maharry, K; Marcucci, G; Mayer, RJ; Moore, JO; Mrózek, K; Pettenati, MJ; Powell, BL; Ruppert, AS; Schiffer, CA; Sterling, LJ; Vardiman, JW | 1 |
| Amrein, PC; Dodge, RK; Godfrey, S; Kolitz, J; Lee, EJ; Moore, JO; Powell, B; Robert, F; Schiffer, CA | 1 |
| Allen, SL; Amrein, PC; George, SL; Lee, EJ; Paciucci, PA; Schiffer, CA | 1 |
| Davis, RB; Lee, EJ; Mayer, RJ; Peterson, BA; Schiffer, CA | 1 |
| Egorin, MJ; Lee, EJ; Nayar, MS; Schiffer, CA; Shulman, P; Van Echo, DA | 1 |
3 trial(s) available for diaziquone and Acute Disease
| Article | Year |
|---|---|
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Splenomegaly; Survival Analysis; Treatment Outcome | 2005 |
Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Bone Marrow; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Granulocytes; Humans; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Mitoxantrone; Pilot Projects; Platelet Count; Recombinant Proteins; Remission Induction | 1997 |
An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia: results of 8722, a randomized phase II study conducted by Cancer and Leukemia Group B.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone | 1998 |
3 other study(ies) available for diaziquone and Acute Disease
| Article | Year |
|---|---|
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Chromosome Aberrations; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Proportional Hazards Models; Prospective Studies; Remission Induction; Statistics, Nonparametric; Survival Analysis | 2005 |
Combination chemotherapy with diaziquone and amsacrine in relapsed and refractory acute nonlymphocytic leukemia: a Cancer and Leukemia Group B Study.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Agents; Aziridines; Azirines; Benzoquinones; Female; Humans; Leukemia; Male; Middle Aged | 1987 |
Diaziquone given as a continuous infusion is an active agent for relapsed adult acute nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Aziridines; Azirines; Benzoquinones; Female; Humans; Kinetics; Leukemia; Male; Middle Aged; Platelet Count; Recurrence | 1986 |